{"name":"ORIYOMI OMOTOYOSI AKINYOTU","slug":"oriyomi-omotoyosi-akinyotu","ticker":"","exchange":"","domain":"","description":"ORIYOMI OMOTOYOSI AKINYOTU is a pharmaceutical company with a focus on the development and marketing of anti-malarial drugs. The company has one marketed product, Sulphadoxine-Pyrimethamine, which is used in the treatment of malaria. Limited financial and operational data is available.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sulphadoxine-Pyrimethamine","genericName":"Sulphadoxine-Pyrimethamine","slug":"sulphadoxine-pyrimethamine","indication":"Malaria (Plasmodium falciparum and other Plasmodium species)","status":"marketed"}]}],"pipeline":[{"name":"Sulphadoxine-Pyrimethamine","genericName":"Sulphadoxine-Pyrimethamine","slug":"sulphadoxine-pyrimethamine","phase":"marketed","mechanism":"Sulphadoxine-pyrimethamine inhibits dihydrofolate reductase and dihydropteroate synthase in parasites, blocking folate synthesis and DNA replication.","indications":["Malaria (Plasmodium falciparum and other Plasmodium species)","Toxoplasmosis prophylaxis and treatment","Pneumocystis jirovecii pneumonia prophylaxis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}